BEAT – DKD Biomarker enterprise to attack DKD,,en,Permanent Link to BEAT – DKD Biomarker enterprise to attack DKD,,en,June 8th, 2016,,en,Summary,,en

June 8th, 2016 Posted by Lavori No Comment yet

Summary

Diabetic kidney disease (DKD) is a common complication of diabetes, and DKD is now the most common form of chronic kidney disease. There is no effective way to prevent or treat DKD, leaving many patients in extremely poor health and facing high mortality rates. The BEAt-DKD project aims to deliver tools and knowledge that will facilitate the development of new, personalised treatments for DKD. Among other things, the project will identify and validate biological markers (biomarkers) to help researchers track whether a patient’s condition has worsened, and whether a treatment is working for them. They will also work to identify different sub-groups of patients that could respond differently to certain treatments. The results will therefore pave the way for the development of effective personalised treatments for DKD.,en

.

Funded under the,,it,:,,en,H2020-EU.3.1.7. – Innovative Medicines Initiative 2 (IMI2),,en,Participants,,en,EFPIA companies,,en,AbbVie Inc., North Chicago, Illinois, United States,,en,Astellas Pharma Europe BV, Leiden, Netherlands,,en,Bayer AG, Berlin, Germany,,en,Boehringer Ingelheim International GmbH, Ingelheim, Germany,,en,Eli Lilly And Company Ltd, Basingstoke, United Kingdom,,en,Novo Nordisk A/S, Bagsvaerd, Denmark,,en,Sanofi-Aventis Germany GmbH, Frankfurt / Main, Germany,,de,Universities, research organisations, public bodies, non-profit groups,,en,University Hospital Groningen, Groningen, Netherlands,,nl,Chu Hospitals From Bordeaux, Talence, France,,fr,Institute for Pharmacological Research Mario Negri, Milan, Italy,,it,University of Eastern Finland, Kuopio, Finland,,fi,The University Hospital Regensburg, Regensburg, Germany,,de:

H2020-EU.3.1.7. – Innovative Medicines Initiative 2 (IMI2)

.

Participants

EFPIA companies

  • AbbVie Inc., North Chicago, Illinois, United States
  • Astellas Pharma Europe BV, Leiden, Netherlands
  • Bayer AG, Berlin, Germany
  • Boehringer Ingelheim International GmbH, Ingelheim, Germany
  • Eli Lilly And Company Ltd, Basingstoke, United Kingdom
  • Novo Nordisk A/S, Bagsvaerd, Denmark
  • Sanofi-Aventis Deutschland GMBH, Frankfurt / Main, Germany

Universities, research organisations, public bodies, non-profit groups

  • Academisch Ziekenhuis Groningen, Groningen, Netherlands
  • Chu Hopitaux De Bordeaux, Talence, France
  • Istituto Di Ricerche Farmacologiche Mario Negri, Milano, Italy
  • Itä-Suomen Yliopisto, Kuopio, Finland
  • Klinikum Der Universitaet Regensburg, Regensburg, Germany
  • Lund University, Lund, Sweden,,sv,Medical University of Vienna, Vienna, Austria,,de,Innsbruck Medical University, Innsbruck, Austria,,de,SIB Swiss Institute of Bioinformatics From CH-660-0733998-3, Geneva, Switzerland,,fr,The University Of Exeter, Exeter, United Kingdom,,en,Universitaetsklinikum Freiburg, Freiburg, Germany,,en,Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany,,en,University Of Bristol, Bristol, United Kingdom,,en,University Of Dundee, Dundee, United Kingdom,,en,University Of Helsinki, University Of Helsinki, Helsinki, Finland,,en,University Of Hull, Hull, United Kingdom,,en,University Of Leeds, Leeds, United Kingdom,,en,University Of Oxford, Oxford, United Kingdom,,en,University Of Turku, Turku, Finland,,en,Università Degli Studi Di Bari Aldo Moro, Bari, Italy,,it,University of Erlangen-Nuremberg, Erlangen, Germany,,de
  • Medizinische Universitaet Wien, Vienna, Austria
  • Medizinische Universität Innsbruck, Innsbruck, Austria
  • SIB Institut Suisse De Bioinformatique, CH-660-0733998-3, Genève, Switzerland
  • The University Of Exeter, Exeter, United Kingdom
  • Universitaetsklinikum Freiburg, Freiburg, Germany
  • Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany
  • University Of Bristol, Bristol, United Kingdom
  • University Of Dundee, Dundee, United Kingdom
  • University Of Helsinki, University Of Helsinki, Helsinki, Finland
  • University Of Hull, Hull, United Kingdom
  • University Of Leeds, Leeds, United Kingdom
  • University Of Oxford, Oxford, United Kingdom
  • University Of Turku, Turku, Finland
  • Università Degli Studi Di Bari Aldo Moro, Bari, Italy
  • Universitätsklinikum Erlangen, Erlangen, Germany

Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover),,en,Lipotype GmbH, Dresden, Germany,,en,Associated partners,,en,Jdrf International, New York, United States,,en,Third parties,,en,Apuliabiotech, Bari, Italy,,en,Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom,,en,Southwest Finland The Hospital District Federation of Municipalities (Turku University Hospital), Turku, Finland,,fi,Non EFPIA companies,,en,University Of Michigan The Regents Of The University Of Michigan, Ann Arbor, United States,,en,BEAT – DKD Biomarker enterprise to attack DKD | Apuliabiotech,,en

  • Lipotype GmbH, Dresden, Germany

Associated partners

  • Jdrf International, New York, United States

Third parties

  • Apuliabiotech, Bari, Italy
  • Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
  • Varsinais-Suomen Sairaanhoitopiirin Kuntayhtymä (Turku University Hospital), Turku, Finland

Non EFPIA companies

  • University Of Michigan The Regents Of The University Of Michigan, Ann Arbor, United States

.

The comments are closed.